Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer (TVATLC01)
Phase I/II Trial of Tumor Vaccine in Post Radical Operation Patients With Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Outline: After successful vaccine manufacturing, patients receive neoantigen tumor vaccine hypodermically (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years). Treatment continues in the absence of disease recurrence and metastasis or unacceptable toxicity.
Patients are followed for 2 years or up to the absence of disease recurrence and metastasis.
Projected accrual: A total of 30 patients will be accrued for this study.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Nong Yang, MD
- Phone Number: +86 731 89762323
- Email: yangnong0217@163.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Provincal Tumor Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18 to 70 years, Male or Female
- Histological or cytologically diagnosis of lung adenocarcinoma
- After surgical treatment (lobectomy and systematic lymph node dissection)
- Pathological stage IIIA (According to the IASLC Lung Cancer Staging (eight Edition))
- Postoperative standard treatment (platinum-based double-drug adjuvant treatment with or without chemotherapy) or no adjuvant treatment
- Have potential dynamic tumor biomarkers
- Able and willing to give witnessed, written informed consent form prior to receiving any study related procedure, agree to participate in long-term follow-up for up to 3 years
Exclusion Criteria:
- Age < 18 or< 70 years
- Lung squamous cell carcinoma, small cell lung cancer, large cell lung cancer
- Without surgical treatment
- Pathological stage I、II、IIIB、IIIC or IV (According to the IASLC Lung Cancer Staging (eight Edition))
- Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study vaccine
- Drug or alcohol abusers
- Pregnant or breast-feeding patients
- History of immunodeficiency disease or autoimmune disease
- Patients with chronic disease which is undergoing immune reagents or hormone therapy
- Concurrent other medical condition that would prevent the patient from undergoing protocol-based therapy
- Lack of availability of a patient for immunological and clinical follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tumor Vaccine
Injection of NeoAntigen Tumor Vaccine
|
NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease-free Survival (DFS)
Time Frame: Approximately 2 years
|
The time that participants stay free of cancer after surgery following administration of tumor vaccine
|
Approximately 2 years
|
|
Adverse Events (AEs)
Time Frame: 30 days from first study vaccine administration
|
Number of participants experiencing clinical and laboratory adverse events
|
30 days from first study vaccine administration
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Wenxiang Wang, MD, PhD, Hunan Provincal Tumor Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TVATLC01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.